David Escobar

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, David Escobar sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting later-stage tilt upper half by trial count

David Escobar: 1 sponsored US clinical trial, 1 recruiting.

David Escobar sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Parkinson Disease, with 1 trials.

Mid-pack sponsor footprint

David Escobar is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING Phase 4

Personalized Real-Time DBS and PD Mechanisms

NCT06013956

Phase Distribution

PhaseTrial count
Phase 4 1

Therapeutic Areas

Parkinson Disease 1

Where David Escobar enrollment is open (later-stage tilt)

1 recruiting of 1 indexed (100% open).

Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Parkinson Disease (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

David Escobar: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

David Escobar sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share David Escobar1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
David Escobar sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

David Escobar sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this David Escobar page

1 registered trials is a research-attention snapshot, not an endorsement of David Escobar or any single study.

  • 1 of David Escobar's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Parkinson Disease is the condition David Escobar studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Parkinson Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

David Escobar pipeline card: 1 registered trials from official public datasets.Report a data error.